ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
about
Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's diseaseNicotine from cigarette smoking and diet and Parkinson disease: a review.Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease.Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeysEvidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function miceAnalysis of gait in rats with olivocerebellar lesions and ability of the nicotinic acetylcholine receptor agonist varenicline to attenuate impairmentsα6-Containing nicotinic acetylcholine receptors in midbrain dopamine neurons are poised to govern dopamine-mediated behaviors and synaptic plasticityCholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditionsRadiation dosimetry of [(18)F]VAT in nonhuman primates.α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesiasThe nicotinic α6 subunit gene determines variability in chronic pain sensitivity via cross-inhibition of P2X2/3 receptorsPharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease.Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.The use of nonhuman primate models to understand processes in Parkinson's disease.The striatal cholinergic system in L-dopa-induced dyskinesias.
P2860
Q21131066-64A2DD0B-6408-44D8-BCEE-E41B0A78F5E9Q33862534-04E4160E-4338-45F4-8B50-2A0CE4B3E58DQ33917311-43DE17B0-16AF-4A1A-8B6A-2A4EB3DBA69CQ34112026-8A8FBE96-D70C-4D52-99F5-0E7302CB2BD7Q34186299-EB86F563-9063-4019-A0E7-C21819EEDDA7Q35533526-2A623839-E422-4205-AE5D-DE7E7FBBC910Q35836503-56B2B0F4-046A-427B-BB99-4E4AF320E351Q35991554-0C1DE7F2-93D3-43FF-8DE9-84F7C9EA3934Q36042479-32A78C24-BC13-479F-9059-DCA97C2FEE59Q36363218-D0AFF934-2077-4E88-B34B-DCEDECE9E4C1Q36469995-D016648F-44B3-4164-8B45-3F259623CD9AQ36880148-3A3EA5BF-8F02-43E0-A408-61CA78487FC5Q37246699-06685371-CC46-4E7E-B096-1B525F208DA9Q38262418-DC177818-3495-4F43-B12D-4CEBFE7BA40FQ38532889-1004FF67-D332-4A9D-9869-D2BE10D0263CQ38629277-6C20B8D2-7EEB-4D93-8391-F2D226ACBDC9Q39208290-7D10178A-DC68-46FF-9B2D-0C6700DAC195Q52680310-C795AE1D-9948-4416-A95F-3EFD074E10B4
P2860
ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ABT-089 and ABT-894 reduce lev ...... model of Parkinson's disease.
@en
ABT-089 and ABT-894 reduce lev ...... model of Parkinson's disease.
@nl
type
label
ABT-089 and ABT-894 reduce lev ...... model of Parkinson's disease.
@en
ABT-089 and ABT-894 reduce lev ...... model of Parkinson's disease.
@nl
prefLabel
ABT-089 and ABT-894 reduce lev ...... model of Parkinson's disease.
@en
ABT-089 and ABT-894 reduce lev ...... model of Parkinson's disease.
@nl
P2093
P2860
P921
P356
P1433
P1476
ABT-089 and ABT-894 reduce lev ...... model of Parkinson's disease.
@en
P2093
Danhui Zhang
J Michael McIntosh
Maryka Quik
Matthew McGregor
Michael W Decker
Tanuja Bordia
P2860
P304
P356
10.1002/MDS.25817
P407
P577
2014-02-11T00:00:00Z